Growth hormone secretagogue receptor type 1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Growth hormone secretagogue receptor type 1 shows approved-linked disease relevance led by Diagnostic Techniques, Endocrine. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q92847. Start with Diagnostic Techniques, Endocrine, then reuse UniProt Q92847 as the stable protein anchor across project notes and exports.
Start with Diagnostic Techniques, Endocrine, then reuse UniProt Q92847 as the stable protein anchor across project notes and exports.
Growth hormone secretagogue receptor type 1 shows approved-linked disease relevance led by Diagnostic Techniques, Endocrine. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Diagnostic Techniques, Endocrine because it currently carries approved-linked support. Linked drugs include MACIMORELIN ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGrowth hormone secretagogue receptor type 1
Review this target as Growth hormone secretagogue receptor type 1, mapped to UniProt Q92847. Sequence length is 366 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Growth hormone secretagogue receptor type 1 as ChEMBL target CHEMBL4616, mapped to UniProt Q92847. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Growth hormone secretagogue receptor type 1 is the right protein anchor across sources, using UniProt Q92847 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Diagnostic Techniques, Endocrine is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Growth hormone secretagogue receptor type 1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q92847 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Growth hormone secretagogue receptor type 1 |
| UniProt Accession | Q92847 |
| Component Type | Protein |
| Sequence Length | 366 aa |
Growth hormone secretagogue receptor type 1
Review this target as Growth hormone secretagogue receptor type 1, mapped to UniProt Q92847. Sequence length is 366 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Growth hormone secretagogue receptor type 1 shows approved-linked disease relevance led by Diagnostic Techniques, Endocrine. 5 more disease programs remain visible in the same review block.
Start review with Diagnostic Techniques, Endocrine because it currently carries approved-linked support. Linked drugs include MACIMORELIN ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1956993 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL1956994 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL178475 | 10.7 | IC50 | 0.02 | Preclinical |
| CHEMBL1957010 | 10.3 | Ki | 0.05 | Preclinical |
| CHEMBL480821 | 10.3 | EC50 | 0.05012 | Preclinical |
| CHEMBL3319217 | 10.11 | IC50 | 0.078 | Preclinical |
| CHEMBL501253 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL1923609 | 10.0 | Ki | 0.1 | Preclinical |
| CHEMBL1923610 | 10.0 | Ki | 0.1 | Preclinical |
| CHEMBL1923623 | 10.0 | Ki | 0.1 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 198 | 715 | 7.5 |
| assay format | 30 | 431 | 7.8 |
| single protein format | 7 | 0 | — |
| organism-based format | 3 | 4 | 9.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 66 | 304 | 7.1 |
| cell-based format | 65 | 963 | 7.4 |
| assay format | 2 | 39 | 8.9 |
| cell membrane format | 1 | 2 | 9.7 |
| tissue-based format | 1 | 0 | — |